Tioga Pharmaceuticals, Inc. announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) on Special Protocol Assessments (SPAs) for the Phase 3 efficacy protocols for its product candidate, asimadoline, for the treatment of patients with diarrhea-predominant irritable bowel syndrome (D-IBS)...View the full article
Medical News Today- Tioga Pharmaceuticals Receives Special Protocol Assessment Agreement From FDA For Phase 3 Trials Of Asimadoline In Irritable Bowel
Join the discussion
